Results 11 to 20 of about 3,703,394 (160)

Statistical Analysis of High Content Screening Data [PDF]

, 2009
High throughput screening experiments are typically used within the pharmaceutical industry for the identification and evaluation of candidate drugs. Using a high throughput screen with automated imaging platform allows a large number of compounds to be ...
Jacques, Richard
core   +6 more sources

Novel network pharmacology methods for drug mechanism of action identification, pre-clinical drug screening and drug repositioning [PDF]

, 2011
The high rates of failure in oncology drug clinical trials highlight the problems of using pre-clinical data to predict the clinical effects of drugs. Here we present two methodology innovations on network pharmacology modeling.
Jianghui Xiong
core   +1 more source

Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening. [PDF]

, 2010
BACKGROUND: In view of the current widespread use of and reliance on a single schistosomicide, praziquantel, there is a pressing need to discover and develop alternative drugs for schistosomiasis.
Bickle, Quentin D, Mansour Nuha R., Nuha R Mansour, Mansour, Nuha R, Bickle Quentin D., Nuha R. Mansour, Quentin D Bickle, Quentin D. Bickle   +7 more
core   +1 more source

Drug-drug interactions in the hospital [PDF]

, 2007
Introduction Drug interaction screening programs are an important tool to check prescriptions of multiple drugs for potential drug-drug interactions (pDDIs). Several programs are available on the market.
Vonbach, Priska
core   +1 more source

Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. [PDF]

, 2012
Sole reliance on one drug, Praziquantel, for treatment and control of schistosomiasis raises concerns about development of widespread resistance, prompting renewed interest in the discovery of new anthelmintics.
Bickle, Quentin D, Bickle, Quentin D., Mansour Nuha R., Gilbert, Ian H, Alex E Benn, Bickle Quentin D., Ian H Gilbert, Nuha R. Mansour (146895), Andrew L. Hopkins (146939), Ivana Mikic (146920), Benn Alex E., Guidi Alessandra, Leo S. Bleicher (146907), Hopkins, Andrew L, Gilbert, Ian H., Bleicher Leo S., Hopkins Andrew L., Guidi, Alessandra, Benn, Alex E., Ivana Mikic, Quentin D. Bickle (146947), Alex E. Benn (146913), Irene Hallyburton (146900), Ian H. Gilbert (146934), Bleicher, Leo S, Alessandra Guidi (146927), Mansour, Nuha R., Paveley, Ross A., Alessandra Guidi, Bleicher, Leo S., Ross A Paveley, Irene Hallyburton, Quentin D Bickle, Hallyburton, Irene, Paveley Ross A., Paveley, Ross A, Mikic Ivana, Nuha R Mansour, Ross A. Paveley (146889), Mansour, Nuha R, Leo S Bleicher, Mikic, Ivana, Hopkins, Andrew L., Andrew L Hopkins, Hallyburton Irene, Gilbert Ian H., Benn, Alex E   +46 more
core   +2 more sources

Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma

Journal of Enzyme Inhibition and Medicinal Chemistry, 2021
Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumour in the central nervous system (CNS). As the ideal targets for GBM treatment, Src family kinases (SFKs) have attracted much attention.
Lishun Zhang, Zichao Yang, Huiting Sang, Ying Jiang, Mingfeng Zhou, Chuan Huang, Chunhui Huang, Xiaoyun Wu, Tingting Zhang, Xingmei Zhang, Shanhe Wan, Jiajie Zhang   +11 more
doaj   +1 more source

Integrated dataset of screening hits against multiple neglected disease pathogens. [PDF]

, 2011
New chemical entities are desperately needed that overcome the limitations of existing drugs for neglected diseases. Screening a diverse library of 10,000 drug-like compounds against 7 neglected disease pathogens resulted in an integrated dataset of 744 ...
Clive Yeates, Mansour Nuha R., Ridley, Robert, Simon Townson, Nwaka, S, Dominique Besson, Yeates, Clive, Townson, Simon, Yeates Clive, Jean-Marc Paris, Geary Timothy, Murthy P. K., Ramirez, Bernadette, Maes, Louis, Ramirez Bernadette, Besson, D, Yousif, F, Yousif Fouad, Samje, M, Solomon Nwaka, Van Voorhis Wesley C., Ramirez, B, Misra-Bhattacharya, S, Samje, Moses, An Matheeussen, Ridley, R, Murthy, PK, Suzanne Gokool, Cho-Ngwa Fidelis, Bickle, Q, P K Murthy, Timothy Geary, Bickle Quentin, Gokool, Suzanne, Bernadette Ramirez, Fidelis Cho-Ngwa, Geary, Timothy, Paris, Jean-Marc, Geary, T, Maes, L, Paris Jean-Marc, Quentin Bickle, Fakorede, Foluke, Shailja Misra-Bhattacharya, Samje Moses, Moses Samje, Van Voorhis, WC, Bickle, Quentin, Matheeussen, A, Besson, Dominique, Fouad Yousif, Gokool Suzanne, Louis Maes, Van Voorhis, Wesley C, Townson, S, Fakorede, F, Yousif, Fouad, Cho-Ngwa, F, Nwaka, Solomon, Maes Louis, Townson Simon, Nwaka Solomon, Wesley C Van Voorhis, Misra-Bhattacharya, Shailja, Ridley Robert, Cho-Ngwa, Fidelis, Robert Ridley, Matheeussen An, Fakorede Foluke, Besson Dominique, Mansour, NR, Matheeussen, An, Paris, JM, Foluke Fakorede, Nuha R Mansour, Mansour, Nuha R, Yeates, C, Gokool, S, Misra-Bhattacharya Shailja, et al.   +79 more
core   +2 more sources

Hypoglycemic effect of Camellia chrysantha extract on type 2 diabetic mice model

Bangladesh Journal of Pharmacology, 2017
The aim of this study was to investigate the hypoglycemic effect of Camellia chrysantha using type 2 diabetic mice model. The ethyl acetate/dichloromethane extract exhibited the most effective hypoglycemic effect.
Lai Wang, Debmalya Roy, Sen Sen Lin, Sheng Tao Yuan, Li Sun   +4 more
doaj   +1 more source

SRT1720 Alleviates ANIT-Induced Cholestasis in a Mouse Model

Frontiers in Pharmacology, 2017
Intrahepatic cholestasis is a kind of clinical syndrome along with hepatotoxicity which caused by intrahepatic and systemic accumulations of bile acid. There are several crucial generating factors of the pathogenesis of cholestasis, such as inflammation,
Linxi Yu, Xiaoxin Liu, Zihang Yuan, Xiaojiaoyang Li, Hang Yang, Ziqiao Yuan, Lixin Sun, Luyong Zhang, Luyong Zhang, Luyong Zhang, Zhengzhou Jiang, Zhengzhou Jiang   +11 more
doaj   +1 more source

Microfluidic trends in drug screening and drug delivery

, 2023
The low probability of a drug candidate's clinical success, the time consumed and the high cost of bringing a drug from concept to market emphasizes the need for new approaches to drug discovery. Recent innovations in microfluidic technologies, including
Feng, Jianguo, Neuzil, Pavel, Neuzil, Jiri, Iliescu, Ciprian, Manz, Andreas   +4 more
core   +1 more source